Drugs / Donepezil
Donepezil
also known as
Aricept · Donepezil hydrochloride · E2020 · Donepezil HCl · E2022 · Aricept (donepezil) · Donepezil (generic name) · GB-5001 · +27 more
Small molecule targets ACHE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed Alzheimer disease 3 milestones | |||||
| Filed | China (NMPA) | Aricept® | Alzheimer disease | 2015-03-03 | “New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept® (donepezil hydrochloride, brand name in China: 安理申®) has been accepted” eisai.com ↗ |
| Filed | US (FDA) | Aricept | Alzheimer disease | 2009-11-25 | “the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application for Aricept® 23 mg” eisai.com ↗ “In June 2010, Teikoku USA submitted an NDA to the FDA seeking approval to use Aricept® transdermal patch” eisai.com ↗ |
| Filed | Japan (PMDA) | Aricept | Alzheimer disease | 2008-03-14 | “severe Alzheimer's disease has already been approved in the USA, India, New Zealand and Philippines. In addition, the application has been submitted in Japan.” eisai.com ↗ “announced today that the company submitted an application for a new oral jelly formulation of Aricept ® (donepezil hydrochloride) in Japan.” eisai.com ↗ |
| Filed Lewy body dementia 1 milestone | |||||
| Filed | Japan (PMDA) | Aricept® | Lewy body dementia | 2013-10-31 | “announced today that it has filed an application for the anti-Alzheimer's agent Aricept® (donepezil hydrochloride, “donepezil”) in Japan” eisai.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Refused (EMA) | EU (EMA) | Balaxur | — | 2013-02-20 | europa.eu ↗ |
| Label expansion | US (FDA) | ARICEPT ODT | — | 2006-10-13 | fda.gov ↗ |
| Approved | US (FDA) | ARICEPT | — | 1996-11-25 | fda.gov ↗ |
Trials 189 · started per year
today
US approved 1996
1
1
3
2
3
7
8
7
10
11
14
15
4
8
11
8
7
9
8
9
3
6
4
4
4
7
3
5
2
2
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05438264 | Mar 2023 → Sep 2026 overdue | sensorineural hearing loss disorder | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05540977 | Aug 2022 → May 2023 | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 0 | NCT03599726 | Jul 2018 → May 2019 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 0 | NCT00452868 | Jun 2006 → Feb 2010 | central nervous system neoplasm, chemotherapy-induced toxicity, cognitive disorder, radiation-induced disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 153 trials · 3 met primary · 2 missed | ||||||
| Phase 1 | NCT07799090 | Aug 2025 → Apr 2026 | — | G2GBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06373094 | Jun 2024 → Mar 2025 | Alzheimer disease | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06127368 | Jan → Sep 2024 | Alzheimer disease | G2GBio, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05804279 | Dec 2022 → Feb 2023 | — | Hyundai Pharm | Completed | No outcome recorded |
| Phase 1 | NCT05525780 | Aug 2022 → Jun 2023 | Alzheimer disease | G2GBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05127746 | Nov 2021 → Dec 2022 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04730635 | Mar 2021 → Jan 2023 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04308304 | Feb 2021 → May 2022 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04479865 | Jul → Dec 2020 | — | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03905096 | Apr → Aug 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03569579 | Apr → May 2018 | central nervous system disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03438604 | Feb → Jun 2018 | Alzheimer disease | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03432195 | Jan → Jun 2018 | Alzheimer disease | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03397862 | Nov 2017 → Mar 2018 | skin disorder | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03030105 | Jan → May 2017 | Alzheimer disease | Tetra Discovery Partners | Completed | No outcome recorded |
| Phase 1 | NCT02918266 | Nov 2016 → Aug 2017 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02968719 | Nov 2016 → Jul 2017 | Alzheimer disease | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02769065 | May 2016 → Jun 2017 | Alzheimer disease | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02635750 | Jan → Mar 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02406261 | Apr → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02225288 | Sep → Dec 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02178124 | Jul → Dec 2014 | Alzheimer disease | Icure Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02051335 | Jan → May 2014 | Alzheimer disease | AstraZeneca | Completed | Mixed |
| Phase 1 | NCT02055703 | Jan → Apr 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01903824 | Aug → Oct 2013 | cognitive disorder | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01860625 | Apr → Dec 2013 | Alzheimer disease | Icure Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01843556 | Dec 2012 → Apr 2013 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02042729 | Aug → Oct 2012 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01584076 | Aug 2012 → Jan 2021 | amblyopia | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01461174 | Nov 2011 → Nov 2014 | — | Qualissima | Completed | No outcome recorded |
| Phase 1 | NCT01485185 | Oct 2011 → Jul 2012 | neuropathy, painful | GlaxoSmithKline | Completed | Mixed |
| Phase 1 | NCT01450839 | Sep → Nov 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01345864 | May → Jul 2011 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01253434 | Nov 2010 → Mar 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01923259 | Oct 2010 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01923558 | Oct 2010 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01097876 | Apr → Jul 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01042314 | Jan → Apr 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00874939 | Apr 2009 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00713765 | Dec 2008 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00777608 | Dec 2008 → Oct 2009 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 1 | NCT00750529 | Nov 2008 → Sep 2013 | Alzheimer disease | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00766363 | Oct 2008 → Mar 2009 | Alzheimer disease | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01297036 | Jan → Mar 2008 | Alzheimer disease | Korea University Anam Hospital | Completed | Met primary |
| Phase 1 | NCT00887601 | Aug 2007 → May 2008 | dementia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01439243 | Jun → Jul 2007 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01439230 | Jun → Aug 2007 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01181310 | Jun → Oct 2007 | dementia | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 1 | NCT00457769 | May 2007 → Dec 2021 | stroke disorder, vascular dementia | Kessler Foundation | Unknown | No outcome recorded |
| Phase 1 | NCT00408525 | Dec 2006 → Aug 2012 | Alzheimer disease | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01260948 | Apr → May 2006 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT01260922 | Apr → May 2006 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00220584 | Jul 2005 → Jul 2009 | fragile X syndrome | Stanford University | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05345509 | Apr 2023 → Nov 2025 overdue | Alzheimer disease | Inventage Lab., Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT01442766 | Nov 2011 → Nov 2013 | stroke disorder | Imperial College London | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00695136 | Jun 2008 → Jan 2011 | autism, cognitive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 237 trials · 3 missed | ||||||
| Phase 2 | NCT06518941 | Jun 2026 → Jun 2027 expected | anorexia nervosa | New York State Psychiatric Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06041789 | Feb 2025 → Sep 2027 expected | osteoporosis | Duke University | Recruiting | No outcome recorded |
| Phase 2 | NCT06903910 | Nov 2024 → Jun 2025 | Parkinson disease | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT06687993 | Nov 2024 → Feb 2030 expected | anorexia nervosa | Centre Hospitalier St Anne | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05709301 | Oct 2023 → Nov 2025 | Parkinson disease, cognitive impairment with or without cerebellar ataxia | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05042102 | Aug 2022 → Oct 2026 expected | alcohol-related disorders | VA Connecticut Healthcare System | Recruiting | No outcome recorded |
| Phase 2 | NCT05254639 | Jun 2022 → Jan 2024 | digestive system cancer | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 2 | NCT04505670 | Aug 2020 → Jul 2023 | — | University of Maryland, Baltimore | Unknown | No outcome recorded |
| Phase 2 | NCT04507438 | Jul 2019 → Sep 2023 | type 2 diabetes mellitus | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03907371 | May 2019 → Dec 2022 | cognitive disorder, radiation-induced disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02857244 | Nov 2016 → Nov 2017 | Parkinson disease | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT02860065 | Sep 2016 → Jun 2017 | Alzheimer disease | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Withdrawn | No outcome recorded |
| Phase 2 | NCT02549196 | Oct 2015 → Sep 2017 | Alzheimer disease | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Completed | No outcome recorded |
| Phase 2 | NCT02415062 | Jul 2015 → Oct 2016 | Parkinson disease | Inje University | Unknown | No outcome recorded |
| Phase 2 | NCT02450786 | Jun 2015 → Aug 2019 | Parkinson disease | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT02487082 | Jun 2015 → Dec 2020 | autism spectrum disorder | Stony Brook University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02206620 | Jul 2014 → Jul 2017 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT02064920 | Apr 2014 → Jul 2016 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT02094053 | Sep 2013 → Sep 2016 | Down syndrome | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01887132 | Jun 2013 → Dec 2015 | autism spectrum disorder | National Institute of Mental Health (NIMH) | Terminated | Missed primary |
| Phase 2 | NCT01466270 | Jul 2012 → Oct 2013 | anxiety disorder, breast cancer, cognitive disorder, depressive disorder +1 | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01495195 | Feb 2012 → May 2013 | substance-related disorder | Midwest Biomedical Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT01250977 | Jan → Dec 2011 | — | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00916383 | May → Jun 2009 | irritant dermatitis | Teikoku Pharma USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00805792 | Nov 2008 → Sep 2010 | ischemic stroke | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00675025 | Apr → Nov 2008 | Down syndrome | Eisai Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00598650 | Feb 2008 → Mar 2011 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00543855 | Nov 2007 → Feb 2010 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00467389 | Feb 2007 → Sep 2008 | cocaine dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00348192 | May 2006 → ? | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00103948 | Feb 2005 → Oct 2006 | cognitive impairment with or without cerebellar ataxia | Eisai Inc. | Completed | Missed primary |
| Phase 2 | NCT00911807 | Oct 2004 → Apr 2008 | Alzheimer disease | Ever Neuro Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01146509 | Jan 2003 → Apr 2004 | migraine disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00165659 | Nov 2002 → May 2005 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00047697 | Oct 2002 → Aug 2006 | autism | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00070161 | Jul 2001 → May 2005 | central nervous system neoplasm, radiation-induced disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00139373 | — | progressive supranuclear palsy | Groupe Hospitalier Pitie-Salpetriere | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04318639 | Aug 2018 → Dec 2019 | alcohol-related disorders, cognitive impairment with or without cerebellar ataxia | VA Connecticut Healthcare System | Completed | No outcome recorded |
| Phase 2/3 | NCT03090516 | Aug 2016 → Mar 2020 | Alzheimer disease | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02248636 | Jan 2015 → Oct 2019 | dementia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 326 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT04661280 | Feb 2022 → Aug 2026 overdue | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04134416 | Jan 2019 → Oct 2020 | aphasia, stroke disorder | University of Malaga | Completed | No outcome recorded |
| Phase 3 | NCT02927522 | Sep 2018 → Dec 2021 | avascular necrosis, osteoarthritis, rheumatoid arthritis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03197740 | Oct 2017 → Jul 2020 | Alzheimer disease | Icure Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02550665 | Dec 2014 → Aug 2016 | Alzheimer disease | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01014858 | Jan 2013 → Sep 2014 | Parkinson disease | Newcastle-upon-Tyne Hospitals NHS Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01404169 | Sep 2011 → Jul 2014 | Alzheimer disease | Eisai Inc. | Completed | Met primary |
| Phase 3 | NCT01278407 | Feb 2011 → Mar 2013 | Lewy body dementia | Eisai Inc. | Completed | Missed primary |
| Phase 3 | NCT00868010 | Mar 2009 → Aug 2013 | ischemic stroke | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 3 | NCT00688376 | Jul 2008 → May 2009 | cognitive impairment with or without cerebellar ataxia | Eisai Inc. | Completed | Missed primary |
| Phase 3 | NCT00369785 | Feb 2008 → Jul 2012 | brain neoplasm, metastatic neoplasm | Wake Forest University Health Sciences | Completed | Mixed |
| Phase 3 | NCT00566501 | Dec 2007 → Apr 2010 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00478205 | Jun 2007 → Jun 2009 | Alzheimer disease | Eisai Inc. | Completed | Mixed |
| Phase 3 | NCT00174382 | Jun 2005 → Apr 2008 | vascular dementia | Pfizer | Terminated | Missed primary |
| Phase 3 | NCT00069550 | Sep 2004 → Jun 2008 | Rett syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 3 | NCT00188812 | May 2004 → Aug 2005 | vascular dementia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00165737 | Mar 2003 → Aug 2005 | vascular dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01327859 | Mar 2003 → Jul 2006 | Parkinson disease, dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00630851 | Oct 2002 → Oct 2004 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00165815 | Aug 2002 → Jul 2005 | Parkinson disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00006349 | Feb 2001 → Jan 2005 | delirium, depressive disorder, radiation-induced disorder, small cell lung carcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00096473 | Jan 2001 → Jun 2005 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00062972 | Sep 1999 → Aug 2002 | multiple sclerosis | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 3 | NCT00000173 | Mar 1999 → Jan 2004 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 3 | NCT00190021 | — | Alzheimer disease | Beersheva Mental Health Center | Unknown | No outcome recorded |
| Phase 447 trials · 6 missed | ||||||
| Phase 4 | NCT03454646 | Jun 2024 → Apr 2027 expected | Alzheimer disease | University Hospital, Bordeaux | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07153991 | Nov 2021 → Dec 2025 overdue | tinnitus | University of Sao Paulo | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04423276 | Jun 2020 → Dec 2021 | vertebral column disorder | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04117178 | Feb 2020 → Feb 2023 | Alzheimer disease, Lewy body dementia, Parkinson disease | Zealand University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02787746 | Apr 2016 → Jan 2019 | Alzheimer disease | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02345213 | Mar 2015 → May 2017 | Lewy body dementia | Eisai Inc. | Completed | Missed primary |
| Phase 4 | NCT02264353 | Sep 2014 → May 2015 | obstructive sleep apnea syndrome | University of California, San Diego | Completed | Missed primary |
| Phase 4 | NCT02097056 | Feb 2014 → May 2015 | Alzheimer disease | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01951118 | Oct 2013 → May 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02660983 | Aug 2013 → Jul 2018 | vascular dementia | Eisai Inc. | Completed | Missed primary |
| Phase 4 | NCT01743976 | Dec 2012 → Oct 2013 | neuropathy, painful | Wake Forest University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01633593 | Aug 2012 → Dec 2015 | delirium, myopathy | University of Sao Paulo | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01845636 | Aug 2012 → Mar 2016 | cognitive impairment with or without cerebellar ataxia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01521117 | Dec 2011 → Apr 2012 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT01658228 | Sep 2011 → Jan 2016 | cognitive impairment with or without cerebellar ataxia, depressive disorder | New York State Psychiatric Institute | Completed | Missed primary |
| Phase 4 | NCT01098383 | Mar 2010 → Dec 2017 | autism | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01063556 | Feb → Mar 2010 | end stage renal failure | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00571064 | Jan → Dec 2008 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00477659 | Jul 2007 → Aug 2008 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00482001 | Jun 2007 → Aug 2008 | mental disorder | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 4 | NCT00912457 | Mar 2007 → Dec 2009 | obstructive sleep apnea syndrome | Associacao Fundo de Incentivo a Psicofarmcologia | Unknown | No outcome recorded |
| Phase 4 | NCT00800553 | Nov 2006 → May 2007 | — | Duke-NUS Graduate Medical School | Completed | No outcome recorded |
| Phase 4 | NCT00403520 | Nov 2006 → Mar 2008 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00369603 | Oct 2006 → Oct 2007 | Alzheimer disease | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT00381381 | May 2006 → Aug 2008 | Alzheimer disease | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00934375 | Feb 2006 → Sep 2007 | cognitive impairment with or without cerebellar ataxia | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00220896 | Jan 2006 → Mar 2009 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT03073876 | Dec 2005 → Jul 2009 | Alzheimer disease | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT00230568 | Dec 2005 → Apr 2007 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00165763 | Sep 2005 → Sep 2009 | vascular dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01191918 | May 2005 → Apr 2008 | manic bipolar affective disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT00165750 | Mar 2005 → Aug 2008 | Alzheimer disease | Eisai Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00182845 | Feb 2005 → Apr 2007 | delirium | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00315367 | Sep 2004 → Oct 2007 | relapsing-remitting multiple sclerosis | Neurognostics | Completed | No outcome recorded |
| Phase 4 | NCT00182884 | Jul 2004 → Apr 2007 | delirium | Indiana University Health | Completed | No outcome recorded |
| Phase 4 | NCT00165724 | Jun 2004 → Jul 2006 | Alzheimer disease | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00293176 | Dec 2003 → Mar 2007 | amnestic disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00177671 | Dec 2003 → Sep 2009 | dementia, major depressive disorder | University of Pittsburgh | Completed | Missed primary |
| Phase 4 | NCT00142324 | Nov 2003 → Dec 2005 | Alzheimer disease | Institute of Psychiatry, London | Unknown | Missed primary |
| Phase 4 | NCT00227994 | Apr 2003 → Jan 2005 | stroke disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00196690 | Feb 2003 → Mar 2005 | aphasia, stroke disorder | Gabinete Berthier y Martínez | Completed | No outcome recorded |
| Phase 4 | NCT00042172 | Jun 2002 → Sep 2004 | Alzheimer disease | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT00030979 | Feb 2002 → Mar 2005 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 4 | NCT00267163 | Sep 2000 → Jul 2007 | cognitive disorder | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 4 | NCT02988908 | Apr 2000 → Sep 2007 | — | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00480870 | Apr 1999 → Jan 2005 | Alzheimer disease, obstructive sleep apnea syndrome | Associacao Fundo de Incentivo a Psicofarmcologia | Completed | No outcome recorded |
| Phase 4 | NCT00018278 | Oct 1998 → Sep 2001 | Alzheimer disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable15 trials · 1 met primary · 1 missed | ||||||
| — | NCT07680660 | Jul 2026 → Sep 2028 expected | Alzheimer disease | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| — | NCT05641480 | Jun 2022 → Dec 2025 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, subjective cognitive decline | Shaanxi Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01362686 | Apr 2011 → Oct 2015 | Alzheimer disease | Indiana University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01082965 | Jul 2010 → Jul 2012 | Alzheimer disease | Pfizer | Terminated | Missed primary Stop: Enrollment |
| — | NCT00934531 | Sep 2009 → Jan 2019 | cognitive impairment with or without cerebellar ataxia | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT00776347 | Oct 2008 → Feb 2015 | Lewy body dementia | Osaka University | Completed | No outcome recorded |
| — | NCT01379001 | Jul 2008 → Jan 2013 | — | Hebrew SeniorLife | Completed | No outcome recorded |
| — | NCT01023425 | Feb 2008 → Apr 2009 | Alzheimer disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00533065 | Sep 2007 → Jul 2009 | — | Ludwig Boltzmann Gesellschaft | Completed | No outcome recorded |
| — | NCT01023867 | Mar 2007 → Jun 2010 | Alzheimer disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00912808 | Oct 2005 → Feb 2009 | Parkinson disease | Oregon Health and Science University | Completed | Met primary |
| — | NCT00483028 | Jun 2004 → Jan 2007 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| — | NCT00043589 | Jun 2002 → Dec 2006 | amnestic disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00004807 | Jan 1995 → ? | Rett syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| — | NCT00530478 | — | stroke disorder | Samsung Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy97 trials | ||||||
| Phase 0 | NCT07208344 Background | Jul → Dec 2025 overdue | Alzheimer disease | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06393413 Comparator | Dec 2022 → Dec 2023 | — | Changchun University of Chinese Medicine | Completed | No outcome recorded |
| Phase 0 | NCT05003063 Comparator | Feb → Aug 2021 | — | University of California, Berkeley | Completed | No outcome recorded |
| Phase 0 | NCT01024660 Comparator | Dec 2009 → Jan 2011 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06774261 Comparator | Feb → Dec 2025 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Helse Stavanger HF | Completed | No outcome recorded |
| Phase 1 | NCT07094438 Comparator | Jan 2025 → Jun 2026 overdue | Alzheimer disease | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06285240 Background | Mar → Sep 2024 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04617782 Comparator | Dec 2020 → Apr 2021 | — | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03740178 Background | Sep 2019 → Feb 2020 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT03932916 Comparator | Jul 2019 → Aug 2020 | — | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04013477 Comparator | Jun → Dec 2019 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03802162 Comparator | Feb → May 2019 | Alzheimer disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03316898 Background | Sep → Nov 2018 | Alzheimer disease | Allergan | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03698695 Comparator | Sep 2018 → Oct 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Theranexus | Completed | No outcome recorded |
| Phase 1 | NCT01487395 Comparator | Dec 2011 → Dec 2012 | Alzheimer disease | University Hospital, Lille | Completed | No outcome recorded |
| Phase 1 | NCT01213355 Comparator | Apr → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01044342 Comparator | Dec 2009 → Apr 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00959881 Background | Aug → Nov 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00519298 Comparator | Oct 2007 → Mar 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT05538507 Comparator | Jun 2022 → Jun 2024 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02305836 Comparator | Jun 2017 → Jun 2019 | cognitive disorder | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03055741 Background | Dec 2016 → Feb 2019 | Alzheimer disease | Daehwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01255046 Comparator | Dec 2015 → Dec 2018 | Alzheimer disease | Sinphar Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02580305 Comparator | Sep 2015 → Nov 2019 | Alzheimer disease | Suven Life Sciences Limited | Completed | No outcome recorded |
| Phase 2 | NCT02337907 Comparator | Jan 2015 → Sep 2017 | Alzheimer disease | Boehringer Ingelheim | Completed | Missed primary |
| Phase 2 | NCT02222727 Comparator | Jan 2014 → Nov 2016 | acquired aneurysmal subarachnoid hemorrhage, brain ischemia, intracranial vasospasm | St George's, University of London | Terminated | No outcome recorded |
| Phase 2 | NCT01852110 Background | Oct 2013 → Apr 2016 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 2 | NCT01677754 Background | Oct 2012 → Jun 2015 | Alzheimer disease | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01527916 Comparator | Feb 2012 → Nov 2013 | Alzheimer disease | AbbVie | Completed | Missed primary |
| Phase 2 | NCT01466088 Comparator | Oct 2011 → May 2014 | Alzheimer disease | Targacept Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01266525 Background | Feb 2011 → Jan 2013 | Alzheimer disease | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01276353 Comparator | Jan 2011 → Apr 2012 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01125683 Comparator | Jun 2010 → Mar 2011 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01137526 Comparator | May 2010 → Jul 2011 | Alzheimer disease | AbbVie | Completed | Missed primary |
| Phase 2 | NCT01018875 Comparator | Dec 2009 → Feb 2011 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00948909 Comparator | Oct 2009 → Nov 2010 | Alzheimer disease | AbbVie | Completed | Missed primary |
| Phase 2 | NCT01120626 Comparator | Sep 2009 → Dec 2013 | fragile X syndrome | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00967707 Comparator | Aug 2009 → Apr 2011 | traumatic neuropathy | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT00895895 Comparator | May 2009 → May 2011 | Alzheimer disease | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT00708552 Comparator | Jul 2008 → Mar 2010 | Alzheimer disease | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT00710684 Background | Jul 2008 → May 2010 | Alzheimer disease | GlaxoSmithKline | Completed | Mixed |
| Phase 2 | NCT00693004 Comparator | May 2008 → Jan 2010 | Alzheimer disease | Epix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00602680 Comparator | Jan → Jul 2008 | Alzheimer disease | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT00570128 Comparator | Nov 2007 → Sep 2008 | Down syndrome | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00501111 Comparator | Jul 2007 → Aug 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00586196 Comparator | Jan 2007 → Feb 2013 | delirium | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00151398 Comparator | Oct 2005 → Mar 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00206947 Comparator | Dec 2002 → Jan 2005 | schizophrenia | Birte Glenthoj | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00006399 Background | Sep 1999 → Mar 2004 | Alzheimer disease | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00031018 Background | — | Alzheimer disease | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase 2/3 | NCT07066826 Comparator | Aug 2025 → Aug 2028 expected | Alzheimer disease | Wanbangde Pharmaceutical Group Co., LTD | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05811000 Comparator | Nov 2020 → Feb 2021 | Alzheimer disease | Mediforum Ltd., Co. | Unknown | No outcome recorded |
| Phase 3 | NCT05564169 Background | Jun 2026 → Dec 2028 expected | Alzheimer disease | AB Science | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07060391 Comparator | Jul 2025 → Jan 2027 expected | Alzheimer disease | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03283059 Comparator | Aug 2017 → Sep 2020 | Alzheimer disease | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 3 | NCT02822573 Comparator | May 2017 → Jul 2022 | amnestic disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02453932 Comparator | Oct 2013 → May 2017 | vascular dementia | Dongzhimen Hospital, Beijing | Completed | Met primary |
| Phase 3 | NCT02255799 Comparator | Sep 2013 → Dec 2024 | traumatic brain injury | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01940952 Comparator | Sep 2013 → Aug 2015 | Alzheimer disease | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01539031 Comparator | Mar 2012 → Jan 2015 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01872598 Background | Jan 2012 → Dec 2020 | Alzheimer disease | AB Science | Completed | No outcome recorded |
| Phase 3 | NCT02035982 Comparator | Jul 2010 → May 2014 | Alzheimer disease | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT01451749 Comparator | Sep 2008 → May 2009 | cognitive impairment with or without cerebellar ataxia | North China Pharmaceutical Group Corporation | Completed | Met primary |
| Phase 3 | NCT00754052 Comparator | Sep → Nov 2008 | Down syndrome, cognitive disorder | Eisai Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00754013 Comparator | Sep → Oct 2008 | Down syndrome, cognitive disorder | Eisai Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01245530 Comparator | Jun 2008 → Feb 2011 | Alzheimer disease | Whanin Pharmaceutical Company | Completed | No outcome recorded |
| Phase 3 | NCT00352664 Comparator | Nov 2003 → Jul 2007 | — | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT07604896 Comparator | Jan 2026 → Dec 2027 expected | Alzheimer disease | First Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT03954613 Background | Oct 2020 → Mar 2023 | Alzheimer disease | Neutec Ar-Ge San ve Tic A.Ş | Unknown | No outcome recorded |
| Phase 4 | NCT03299257 Comparator | Jul → Nov 2018 | hypersomnia, obstructive sleep apnea syndrome | Associação Fundo de Incentivo à Pesquisa | Unknown | No outcome recorded |
| Phase 4 | NCT03441516 Comparator | Apr 2018 → Jul 2019 | Alzheimer disease | Yuhan Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT03151382 Background | May → Dec 2017 | Alzheimer disease | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03011476 Comparator | Apr 2017 → Oct 2018 | Parkinson disease | Kyung Hee University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT02087865 Comparator | May 2014 → Dec 2021 | familial Alzheimer disease | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01849042 Background | Jan 2013 → Aug 2014 | Alzheimer disease | Konkuk University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03109314 Comparator | May 2012 → Dec 2018 | amblyopia | Dennis Levi | Completed | No outcome recorded |
| Phase 4 | NCT01490567 Comparator | Jun 2011 → Jun 2012 | schizophrenia | Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT00619983 Comparator | Feb 2008 → May 2013 | chronic pain syndrome, diabetic neuropathy | Wake Forest University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00866060 Comparator | Feb 2008 → Feb 2012 | Alzheimer disease | King's College London | Unknown | No outcome recorded |
| Phase 4 | NCT00711204 Comparator | Jan 2008 → Jun 2009 | Alzheimer disease | Eisai Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00505167 Comparator | Jul 2007 → Jul 2008 | Alzheimer disease | Hospital Miguel Servet | Completed | No outcome recorded |
| Phase 4 | NCT00465283 Comparator | May 2007 → Jan 2010 | schizoaffective disorder, schizophrenia, schizophreniform disorder | BeerYaakov Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT00768261 Comparator | Nov 2004 → Oct 2009 | dementia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01822951 Comparator | ? → Sep 2016 | Alzheimer disease | Ever Neuro Pharma GmbH | Withdrawn | No outcome recorded |
| — | NCT07351773 Background | Jan → Jun 2025 | Alzheimer disease | Taizhou Second People's Hospital | Completed | No outcome recorded |
| — | NCT06417086 Background | Jun 2024 → Nov 2026 expected | Alzheimer disease | ZhanYJ | Recruiting | No outcome recorded |
| — | NCT05078944 Background | Jun 2022 → Sep 2025 | Alzheimer disease type 1 | Shanghai Institute of Acupuncture, Moxibustion and Meridian | Completed | No outcome recorded |
| — | NCT05518409 Background | Apr 2022 → Dec 2023 | Alzheimer disease, Lewy body dementia | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT04732182 Background | Feb → Dec 2022 | Alzheimer disease | Bright Cloud International Corp | Unknown | No outcome recorded |
| — | NCT04754152 Comparator | Apr 2021 → May 2022 | — | Anhui Medical University | Completed | No outcome recorded |
| — | NCT03810794 Background | Mar 2019 → Dec 2026 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Jian Pei,MD | Recruiting | No outcome recorded |
| — | NCT05102045 Background | Sep 2016 → May 2017 | Alzheimer disease | Istanbul Medipol University Hospital | Completed | No outcome recorded |
| — | NCT02331771 Comparator | Sep 2015 → Jan 2017 | cognitive disorder | Porter Adventist Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01738295 Comparator | Jan 2013 → Aug 2014 | — | University of Montreal | Completed | No outcome recorded |
| — | NCT00423228 Comparator | Feb 2007 → Apr 2009 | Alzheimer disease | Debiopharm International SA | Completed | No outcome recorded |
| — | NCT00467766 Background | Jul 1999 → Jun 2003 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 32
| Date | Issuer | Release |
|---|---|---|
| 2026-08-27 | G2GBio, Inc. | Results 지투지바이오, ‘GB-5001’ 임상 1상 다회 투여 안전성·내약성 확인 g2gbio.com ↗
시험 결과 , 투여 기간 동안 중대한 이상반응이나 이상사례로 인한 중도 탈락자가 한 명도 발생하지 않아 우수한 안전성을 입증했다 . |
| 2026-08-06 | G2GBio, Inc. | Results "도네페질 long-acting, 유의미한 성과"… 지투지바이오 'GB-5001', AAIC서 호평 g2gbio.com ↗
이번 GB-5001 발표에는 반복투약시의 안전성과 내약성 그리고 항정상태 도달 양상 및 약동학 등에 대한 결과가 담겨 있다 . |
| 2023-10-16 | G2GBio, Inc. | Regulatory 1개월 지속되는 도네페질 피하주사제 개발 추진…“세계 최초” g2gbio.com ↗
16일 식품의약품안전처에 따르면, 지투지바이오는 'GB-5001'에 대한 임상 1상을 승인받았다. |
| 2023-04-17 | G2GBio, Inc. | Results 지투지바이오, "1개월 도네페질(GB-5001) 제형 개발에 청신호" g2gbio.com ↗ |
| 2022-11-29 | Eisai Inc. | Regulatory EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES eisai.com ↗ |
| 2022-10-31 | Eisai Inc. | Regulatory EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION eisai.com ↗
has been granted Category 2* status based on the results of a reexamination of its efficacy, dosage and administration for the treatment of dementia with Lewy bodies (DLB) in Japan. |
| 2022-06-30 | Inventage Lab., Inc. | Regulatory 인벤티지랩, ‘치매치료 장기지속형 주사제’ 호주 임상 승인 inventagelab.com ↗
약물전달기술 플랫폼 바이오텍 인벤티지랩(대표이사 김주희)은 27일 호주 식품의약품안전청(TGA, Therapeutic Goods Administration)으로부터 치매치료제 IVL3003(성분명: donepezil)의 임상 1/2상 임상시험 계획(IND)을 승인받았다고 밝혔다. |
| 2020-11-04 | Theranexus | Results PRESENTATION OF THE RESULTS OF THE PHASE IB CLINICAL STUDY OF THN201 FOR ALZHEIMER'S DISEASE AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) actusnews.com ↗
In January 2020, the results of the Phase Ib study revealed an extension of the pharmacological profile of the drug candidate THN201 compared to donepezil monotherapy. |
| 2020-01-15 | Theranexus | Results THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG CANDIDATE THN201 COMPARED TO DONEPEZIL actusnews.com ↗
The results revealed an extension of the pharmacological profile of THN201 compared to donepezil monotherapy. |
| 2019-03-27 | Upsher-Smith Laboratories | Regulatory MHLW Approves New Indication for DONEPEZIL Tablets, OD Tablets and Fine Granules upsher-smith.com ↗
today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for DONEPEZIL HYDROCHLORIDE Tablets 3 mg, 5 mg and 10 mg [SAWAI], DONEPEZIL HYDROCHLORIDE OD Tablets 3 mg, 5 mg and 10 mg [SAWAI], and DONEPEZIL HYDROCHLORIDE Fine Granules 0.5 % [SAWAI]*. |
| 2017-12-13 | Eisai Inc. | Regulatory ARICEPT® APPROVED FOR ADDITIONAL INDICATION OF SEVERE ALZHEIMER’S DISEASE IN CHINA eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Aricept® (donepezil hydrochloride, brand name in China: ) has been approved for the additional indication of severe Alzheimer's disease in China. |
| 2016-04-14 | Eisai Inc. | Regulatory ARICEPT® APPROVED IN THE PHILIPPINES FOR NEW INDICATION AS TREATMENT FOR DEMENTIA WITH LEWY BODIES SECOND COUNTRY IN THE WORLD AFTER JAPAN TO APPROVE ARICEPT FOR DEMENTIA WITH LEWY BODIES eisai.com ↗
An application seeking approval for DLB based on clinical trial data from Japan was submitted in November 2015 and subsequently approved in February 2016. |
| 2015-11-03 | Lupin Limited | Regulatory Lupin receives FDA Approval for Generic Aricept® Tablets lupin.com ↗
Mumbai, Baltimore: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai Inc.’s Aricept®, Tablets, 23mg. |
| 2015-03-03 | Eisai Inc. | Regulatory CHINA JSFDA ACCEPTS EISAI'S APPLICATION SEEKING ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE FOR ARICEPT® eisai.com ↗ |
| 2014-09-30 | Eisai Inc. | Results PHASE Ⅲ TRIAL OF ARICEPT® IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE IN CHINA MEETS PRIMARY ENDPOINT eisai.com ↗
Analysis of the results of the study demonstrated that Aricept statistically significantly improved total Severe Impairment Battery scores after 24 weeks compared to placebo, which was the primary endpoint of the study. |
| 2014-09-19 | Eisai Inc. | Regulatory ARICEPT® APPROVED IN JAPAN AS TREATMENT FOR DEMENTIA WITH LEWY BODIES WORLD'S FIRST TREATMENT FOR BOTH ALZHEIMER'S DISEASE AND DEMENTIA WITH LEWY BODIES eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its anti-Alzheimer's agent Aricept® (donepezil hydrochloride) has received approval for a new indication for dementia with Lewy bodies (DLB) in Japan. |
| 2013-10-31 | Eisai Inc. | Regulatory EISAI SUBMITS APPLICATION TO EXPAND INDICATION OF ANTI-ALZHEIMER'S AGENT ARICEPT ® AS TREATMENT FOR DEMENTIA WITH LEWY BODIES IN JAPAN eisai.com ↗ |
| 2011-12-13 | Eisai Inc. | Regulatory EISAI SUBMITS APPLICATION IN JAPAN FOR NEW DRY SYRUP FORMULATION OF ITS ALZHEIMER'S DISEASE TREATMENT ARICEPT® eisai.com ↗
today submitted a marketing and manufacturing authorization application to Japan's Ministry of Health, Labour and Welfare seeking approval of a new dry syrup formulation of its Alzheimer's disease (AD) treatment Aricept® (donepezil hydrochloride). |
| 2011-04-25 | Wockhardt | Regulatory WOCKHARDT RECEIVES US FDA APPROVAL FOR GENERIC VERSION OF ARICEPT® TABLETS wockhardt.com ↗
Pharmaceutical and biotechnology major Wockhardt has received tentative approval from the United States Food & Drug Administration (US FDA) for marketing 5m g and 10mg tablets of Donepezil HCl, which is used for treatment of Alzheimer’s disease and dementia. |
| 2011-04-25 | Eisai Inc. | Regulatory FDA ISSUES COMPLETE RESPONSE LETTER FOR ARICEPT® PATCH (DONEPEZIL TRANSDERMAL SYSTEM) eisai.com ↗
The FDA issues a Complete Response Letter to indicate the review cycle of an application is complete and there are still requirements to be fulfilled. |
| 2011-03-24 | Eisai Inc. | Regulatory LANDMARK RULING COMES INTO EFFECT: TREATMENT NOW AVAILABLE FOR PEOPLE IN ENGLAND AND WALES WITH MILD ALZHEIMER'S AT TIME OF DIAGNOSIS eisai.com ↗
The guidance recommends three Alzheimer's disease medications belonging to a class of drugs known as acetylcholinesterase (AChE) inhibitors, including Eisai's Aricept® (donepezil hydrochloride), as possible options for managing mild to moderate Alzheimer's disease 1) . |
| 2010-11-30 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA tentative approval for generic Aricept® sunpharma.com ↗ |
| 2010-10-07 | Eisai Inc. | Regulatory MILESTONE RULING FOR ALZHEIMER'S DISEASE PATIENTS ANNOUNCED NICE ISSUES NEW DRAFT GUIDANCE eisai.com ↗
The new draft NICE guidance recommends that three key Alzheimer's disease medications (acetylcholinesterase inhibitors), including Aricept® (generic name: donepezil hydrochloride), should be made available to patients in England and Wales as options for managing mild to moderate disease. |
| 2010-09-17 | Eisai Inc. | Regulatory FDA ACCEPTS ARICEPT® PATCH (DONEPEZIL TRANSDERMAL SYSTEM) NDA FOR REVIEW eisai.com ↗
The acceptance of the NDA indicates that the FDA deems the company's submission to be sufficiently complete to review. |
| 2010-07-24 | Eisai Inc. | Regulatory EISAI ANNOUNCES U.S. FDA APPROVAL FOR NEW HIGHER DOSE ARICEPT® 23 MG TABLET FOR THE TREATMENT OF MODERATE-TO-SEVERE ALZHEIMER'S DISEASE eisai.com ↗
announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Aricept® (generic name: donepezil hydrochloride) 23 mg once daily tablet for the treatment of moderate-to-severe Alzheimer's disease (AD). |
| 2009-11-25 | Eisai Inc. | Regulatory FDA Accepts for Review Eisai's NDA for Aricept® 23mg Extended Release Tablets in the United States eisai.com ↗
the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application for Aricept® 23 mg (generic name: donepezil hydrochloride) extended release tablets |
| 2009-07-22 | Eisai Inc. | Regulatory Eisai Receives Approval for a New Oral Jelly Formulation of Aricept® for the Treatment of Alzheimer’s Disease in Japan eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that the Company had received approval for a new oral jelly formulation of Aricept® (donepezil hydrochloride) for the treatment of Alzheimer’s disease from the Japanese Ministry of Health, Labour and Welfare. |
| 2009-07-02 | Eisai Inc. | Regulatory Current Status of the Development Programs of New Indications and Formulations of Aricept® for Enhancing Patient Value eisai.com ↗
Eisai received a notice from the U.S. FDA that there were insufficient grounds to issue a Written Request to obtain pediatric exclusivity. |
| 2008-03-14 | Eisai Inc. | Regulatory Eisai Submits Application for Aricept® Oral Jelly Formulation in Japan eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that the company submitted an application for a new oral jelly formulation of Aricept ® (donepezil hydrochloride) in Japan. |
| 2008-01-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval Of Generic Aricept® Tablets tevapharm.com ↗
the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) |
| 2007-08-23 | Eisai Inc. | Regulatory Aricept® Receives Approval for Additional Efficacy and Dosage For Treatment of Severe Alzheimer's Disease in Japan eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) today announced that the company received approval for additional efficacy and dosage of Aricept ® (donepezil hydrochloride) for the treatment of severe Alzheimer's disease (AD) in Japan. |
| 2007-04-13 | Eisai Inc. | Regulatory Eisai Withdraw Application for Additional Indication of Aricept® for Treatment of Severe Alzheimer's Disease in Europe eisai.com ↗
Eisai Limited (Headquaters: London, Managing Director: Paul Hooper), the U.K. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), today announced that the company has tentatively withdrawn its application for an additional indication for Aricept ® in the treatment of severe Alzheimer's disease, submitted through the mutual recognition procedure in Europe. |
All press releases naming this drug 49 releases
Evidence & citations 40 cited values
Every value below carries the sentence it was read from. 291 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donepezil | “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗257“This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of donepezil...” PMID 40444644 ↗ May 2025 “Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment...” NCT01098383 ↗ “Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe...” NCT01539031 ↗ “A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in...” NCT05345509 ↗ “In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.” NCT01404169 ↗ “A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease” NCT00230568 ↗ “Donepezil will then be added to duloxetine 120mg qam (or the highest dose the patient can tolerate if it is lower than 120mg) by 5mg qd for 1 week, followed by 10mg qd for 1 week.” NCT02857244 ↗ “Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.” NCT07604896 ↗ “Patients in the medication group received only the currently recognized pharmacological treatments for AD, including Memantine Hydrochloride and Donepezil.” NCT07094438 ↗ “23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation” NCT01276353 ↗ |
| Known as | [14C]DONEPEZIL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Adlarity | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Aricept | “And, it is to predict the multiple-dose pharmacokinetics based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept® (donepezil hydrochloride) tablet by...” NCT05525780 ↗41“A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in...” NCT05345509 ↗ “A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease” NCT00230568 ↗ “Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Donepezil 10 mg Tablet and Aricept® (Reference) Following a 10 mg Dose in Healthy Subjects Under Fasting Conditions” NCT01439230 ↗ “Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease” NCT04732182 ↗ “The purpose of this study is to examine the efficacy and safety of cholinesterase inhibitor (donepezil hydrochloride) Aricept in patients with vascular dementia (VaD).” NCT00165763 ↗ “This is a 12-week, randomized, placebo controlled study to determine if donepezil (Aricept) treatment during rehabilitation after stroke improves functional recovery.” NCT00868010 ↗ “The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults.” NCT00042172 ↗ “Participants are instructed to take one 5mg pill (donepezil HCL \[Aricept®\]) every night before going to bed with a glass of water for 28 days.” NCT01250977 ↗ “This study will evaluate the safety and effectiveness of donepezil (Aricept) for treating mild dementia in patients with Parkinson's disease.” NCT00030979 ↗ “This study will evaluate the effectiveness of donepezil (Aricept®) and cognitive training in improving memory performance in elderly adults.” NCT00043589 ↗ |
| Known as | Aricept (donepezil) | “Aricept (donepezil)” NCT01181310 ↗ |
| Known as | Aricept evess | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Aricept odt | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Aricept Tablet | “Aricept Tablet” NCT02968719 ↗ |
| Known as | Aricept(Registered Trademark) | “This study will test whether donepezil (Aricept(Registered Trademark)), a drug that is approved by the Food and Drug Administration to treat Alzheimer's disease” NCT00695136 ↗ |
| Known as | BNAG | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Brand name for donepezil: Aricept | “Brand name for donepezil: Aricept” NCT00911807 ↗ |
| Known as | Corplex Donepezil TDS | “Corplex Donepezil TDS” NCT02968719 ↗ |
| Known as | D797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03802162 ↗ |
| Known as | Donaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | donepezil (Aricept) | “donepezil (Aricept)” NCT00934531 ↗ |
| Known as | Donepezil (generic name) | “Donepezil (generic name)” NCT01439243 ↗1“Donepezil (generic name)” NCT01439230 ↗ |
| Known as | Donepezil Dihydroxynaphthalate | “A Single-center, Open-label, Single-dose Ascending Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of HHT201 (Donepezil...” NCT06373094 ↗ |
| Known as | Donepezil HCI | “Donepezil HCI (Aricept®) is an FDA-approved drug now used to enhance memory in patients with Alzheimer's disease.” NCT00315367 ↗ |
| Known as | Donepezil HCl | “5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.” NCT00165763 ↗4“donepezil HCL (a cholinesterase inhibitor)” NCT02087865 ↗ “Drug: Donepezil HCl” NCT00570128 ↗ “Drug: Donepezil HCl” NCT00047697 ↗ “Drug: Donepezil HCl” NCT00571064 ↗ |
| Known as | Donepezil hydrochloride | “A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo...” PMID 17210817 ↗ Jan 200735“A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe...” NCT01404169 ↗ “And, it is to predict the multiple-dose pharmacokinetics based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept® (donepezil hydrochloride) tablet by...” NCT05525780 ↗ “A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease” NCT00230568 ↗ “This proposal is for a 6 to 20 week, single arm, open-label study to evaluate the ability of donepezil hydrochloride to enhance REM sleep in children with autism spectrum disorder” NCT00695136 ↗ “The purpose of this study is to examine the efficacy and safety of cholinesterase inhibitor (donepezil hydrochloride) Aricept in patients with vascular dementia (VaD).” NCT00165763 ↗ “Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).” NCT00096473 ↗ “Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility” NCT00571064 ↗ “The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)” NCT00293176 ↗ “with either galantamine hydrobromide (AChEI + nicotinic receptor modulation) or donepezil hydrochloride (AChEI only)” NCT00369603 ↗ “Aricept® (donepezil hydrochloride) 5 mg film-coated tablet administered orally as an active comparator” NCT07799090 ↗ |
| Known as | Donepezil Hydrochloride (generic name) | “Donepezil Hydrochloride (generic name)” NCT01260922 ↗ |
| Known as | Donepezil hydrochloride component of namzaric | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | DONEPEZIL HYDROCHLORIDE MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Donepezil TDS | “Drug: Donepezil TDS” NCT03397862 ↗ |
| Known as | Donepezil TDS Version A | “Donepezil TDS Version A” NCT02968719 ↗ |
| Known as | Donepezil TDS Version B | “Donepezil TDS Version B” NCT02968719 ↗ |
| Known as | Donepezil TDS Version D | “Donepezil TDS Version D” NCT02968719 ↗ |
| Known as | Donepezil TDS Version E | “Donepezil TDS Version E” NCT02968719 ↗ |
| Known as | Donepezilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | donezepil | “You will receive Aricept for 5 weeks (donezepil)” NCT00031018 ↗ |
| Known as | E2020 | “A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe...” NCT00096473 ↗6“Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility” NCT00571064 ↗ “Donepezil Hydrochloride (E2020)” NCT00165737 ↗ “E2020-Donepezil hydrochloride” NCT02094053 ↗ “Drug: E2020” NCT01404169 ↗ |
| Known as | E2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01253434 ↗ |
| Known as | GB-5001 | “This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM and SC depot in healthy male Adults.” NCT06127368 ↗1“GB-5001 is an intramuscular (IM) formulation of donepezil under development for the treatment of Alzheimer's disease.” PMID 39126603 ↗ Aug 2024 |
| Known as | IPI-301 | “the test drug, IPI-301 (donepezil transdermal patch), to the comparator, Aricept tablet” NCT03197740 ↗ |
| Known as | NSC-737535 | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | NSC-758882 | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Action | Inhibit | “donepezil, an acetylcholinesterase inhibitor” NCT00030979 ↗1“Acetylcholinesterase inhibitor” CHEMBL502 ↗ |
| Modality | Small molecule | “Donepezil is a piperidine-based reversible, noncompetitive ChEI” NCT00190021 ↗ |
| Route | Oral | “Patients receive oral donepezil daily and vitamin E twice daily.” NCT00006349 ↗ |
| Target | ACHE | “Acetylcholinesterase inhibitor” CHEMBL502 ↗ |